By Fineline Cube MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system has been granted entry into China’s National Medical Products Administration (NMPA) innovative medical device special review procedure (Green Channel). Developed by subsidiary MicroPort NeuroScientific (Shanghai) Co., Ltd., the Artemis Dream represents China’s first domestically developed targeted-drug-release self-expanding intracranial arterial stent, designed to address critical limitations in current neurovascular intervention technologies.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Designation | Innovative Medical Device Special Review (Green Channel) |
| Product | Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system |
| Indication | Intracranial arterial stenosis and vascular reconstruction |
| Developer | MicroPort NeuroScientific (Shanghai) Co., Ltd. (subsidiary of HKG: 2172) |
| Significance | First domestically developed targeted-drug-release self-expanding intracranial stent in China |
Technology Profile & Clinical Innovation
- Stent Architecture: Self-expanding design with optimized balance between mechanical support performance and metal coverage ratio, minimizing vascular injury risk during deployment and long-term implantation
- Drug Delivery System: Directional drug release technology that delivers rapamycin exclusively toward the vessel wall, avoiding systemic exposure and maximizing local therapeutic effect
- Mechanism of Action: Rapamycin inhibits intimal hyperplasia while promoting accelerated endothelialization, addressing the dual challenges of restenosis prevention and vascular healing
- Clinical Benefit: Potential to significantly shorten dual antiplatelet therapy (DAPT) duration post-procedure, reducing bleeding complications and improving patient compliance
- Manufacturing: Fully domestic R&D and production capabilities, supporting China’s strategic goal of medical device self-reliance
Market Context & Unmet Need
Intracranial atherosclerotic disease affects approximately 10-15% of stroke patients in Asia, with higher prevalence rates compared to Western populations. Current treatment options include medical management, angioplasty, and bare-metal stenting, but all are associated with significant limitations including high restenosis rates (20-30%) and extended DAPT requirements (6-12 months).
The global neurovascular devices market is valued at $3.2 billion annually and growing at 8.5% CAGR, driven by aging populations and increasing stroke incidence. However, drug-eluting intracranial stents remain underdeveloped compared to coronary applications, creating substantial opportunity for innovative solutions like Artemis Dream.
Key clinical advantages over existing technologies:
- Reduced restenosis risk through targeted anti-proliferative drug delivery
- Enhanced safety profile via shortened DAPT requirements
- Improved vessel compatibility through optimized mechanical design
- Faster endothelial healing promoting long-term vascular stability
Strategic Implications
- For MicroPort NeuroScientific: Establishes leadership position in next-generation neurovascular interventions and creates potential for global expansion beyond Chinese market
- Competitive Positioning: First-mover advantage in targeted-release intracranial stent segment with significant differentiation from bare-metal and non-targeted drug-eluting alternatives
- Regulatory Pathway: Green Channel designation accelerates approval timeline by 6-12 months compared to standard review process
- Commercial Strategy: Leverage MicroPort’s established neurovascular sales force and hospital relationships for rapid market adoption
Next Steps
- Clinical Trial Initiation: Pivotal trial expected to commence in Q4 2026 with primary endpoints focused on safety, efficacy, and DAPT duration reduction
- Regulatory Timeline: Target NMPA marketing approval by Q2 2028 leveraging Green Channel benefits
- International Strategy: Prepare CE Mark and FDA submissions following successful Chinese approval
- Manufacturing Scale-up: Expand production capacity to meet anticipated commercial demand
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and commercial opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive developments, and market acceptance.-Fineline Info & Tech